Compugen Ltd. is a clinical-stage therapeutic discovery and development company that develops therapeutic and product candidates in Israel, the US, and Europe. Its immuno-oncology pipeline comprises four therapeutic antibodies targeting advanced malignancies and solid tumors, including COM701 and COM902 both in Phase I clinical study. Besides, the Company has collaboration agreements with several institutions for antibody-based therapeutics research and development.